• slider text 2

OUR PRODUCTS

Credo Diagnostics Biomedical develops point-of-care (POC) diagnostic technology.

Our nucleic acid diagnostic platform is designed to be used by any personnel with minimal training. Our solution covers sample preparation, amplification and detection through simple operating procedures with short turnaround time with no compromise on accuracy and sensitivity.

OUR VISION

We at Credo Diagnostics, the pioneers of accessible diagnostic platforms, want to improve the lives of those we love.

We believe providing the right information to the right people at the right time leads to better outcomes.

NEWS

2022
07-26
Credo Diagnostics’ booth at AACC 2022 has officially opened.

Singapore, July 26, 2022 – Credo Diagnostics presents at AACC, Chicago, IL, USA, on July 26 - 28, 2022.

 

At the 2019 AACC in Anaheim, CA, Booth #4339, Credo Diagnostics launched our VitaPCR™ Instrument and our first VitaPCR™ Influenza A&B Assay.

 

After one year, our product lines include the VitaPCR™ SARS-CoV-2 Gen 2 Assay, VitaPCR™ Influenza/SARS-CoV-2 Assay, VitaPCR™ Influenza/RSV Assay, and VitaPCR™ Strep A Assay.
 
For AACC 2022 in Chicago, Credo Diagnostics are happy to announce our participation, and importantly, will introduce our new molecular diagnostic platform – VitaSIRO solo™, and share what we have done since the onset of COVID-19 to help countries provide VitaPCR™ machines.

 

“Today, it is a great honour to see our solutions accepted and requested by users worldwide. We strive to provide the best solutions to our customers continually and we will never stop innovating."
 

Come visit us at Booth #4456 to see for yourself.

 

Credo Diagnostics, “Advanced Medical Technology For All”

 

 Booth #4456, 2022 AACC Annual Scientific Meeting & Clinical Lab Expo

 

About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

view more
2022
07-01
Credo Diagnostics will be present at the AACC event in Chicago, USA.

Singapore, July 1, 2022 - Credo Diagnostics is pleased to announce our participation at the coming 2022 AACC Annual Scientific Meeting & Clinical Lab Expo event from July 26 - 28, 2022 in Chicago, IL, USA.

 

The AACC Annual Scientific Meeting & Clinical Lab Expo is the world’s leading global professional gathering for clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory medicine. It will showcase the cutting-edge science and technology changing the future of laboratory medicine.

 

At the 2019 AACC in Anaheim, CA, Booth #4339, Credo Diagnostics launched the VitaPCR™ Instrument and the first VitaPCR™ Influenza A&B Assay.

 

Today, Credo Diagnostics’ product lines include the VitaPCR™ SARS-CoV-2 Gen 2 Assay, VitaPCR™ Influenza/SARS-CoV-2 Assay, VitaPCR™ Influenza/RSV Assay, and VitaPCR™ Strep A Assay.

 

For the coming 2022 AACC in Chicago, Credo Diagnostics are happy to announce our participation, and importantly, Credo Diagnostics will reveal the arrival of an exciting new platform and a whole series of new Assays.

 

“Today, it is a great honour to see our solutions accepted and requested by users around the world. We strive to continually provide the best solutions to our customers, and we will never stop innovating." said Dr. Wong Jr. Winston, Chairman, and CEO of Credo Diagnostics Biomedical.

 

Come visit Credo Diagnostics at Booth #4456 to see for yourself.

 

Credo Diagnostics, “Advanced Medical Technology For All”

 

About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics Biomedical develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

view more
2022
05-31
VitaPCR™ SARS-CoV-2 RNA detection Assay can correctly detect Omicron sub-lineages BA.4 and BA.5

Singapore, May 31, 2022 – In response to the new Omicron variant (also known as B.1.1.529), we, Credo Diagnostics Biomedical Pte Ltd, have performed the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID on May 25th, 2022.

 

According to our analysis, we confirm that our SARS-CoV-2 RNA detection assay* can correctly detect the new Omicron strain, including B.1.1.529 BA.1, BA.2, BA.4, and BA.5.

 

Meanwhile. we continue to affirm that our SARS-CoV-2 RNA detection assay is still capable of detecting the following earlier variant strains correctly

 

Another circulating Variant of Concern (VOC):

Delta variant: known as B.1.617.2

 

Previously circulating Variants of Concern (VOC):

. Alpha variant: known as B.1.1.7

. Beta variant: known as B.1.351

. Gamma variant: known as P.1

Previously circulating Variants of Interest (VOI)

Lambda variant: known as C.37

Mu variant: known as B.1.621

Eta variant: known as B.1.525

Iota variant: known as B.1.526

Kappa variant: known as B.1.617.1

Zeta variant: known as P.2

Epsilon variant: known as B.1.427/B.1.429

Indian variant: known as B.1.617.3

 

 

* The SARS-CoV-2 RNA detection assays include:

   VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)

   VitaPCR™ SARS-CoV-2 Gen2 Assay (PCRAE0120)

   VitaPCR™ SARS-CoV-2 Assay (PCRAE0114)

 


About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

view more

CONTACT

We at Credo Diagnostics pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.